Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
An abstract is unavailable.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
An analysis of relevant studies in the literature identified strategies to mitigate the effects of time pressure on shared decision making for patients with cancer…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
An abstract is unavailable.
PHILADELPHIA (May 20, 2024) — Adjuvant therapy in patients with clinical T2N0 rectal cancer may currently be underutilized, according to the findings of a study…
Hideho Okada, MD, PhD, discusses cancer immunoprevention through the lens of vaccine approaches in patients with low-grade glioma.
PHILADELPHIA (May 20, 2024) — Pancreatic cancer patients who received single modality neoadjuvant therapy experienced fragmented care, which is care at multiple centers, more often…
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell…
The FDA greenlighted tarlatamab (Imdelltra; Amgen), a bispecific T-cell engager that targets delta-like ligand 3 (DLL3), to treat extensive-stage small cell lung cancer that has…